Rule 3.8A

## Appendix 3E

## Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Nan	ne of entity		ABN/ARSN	
Sig	ma Pharmaceuticals Limited	15 088 417 403		
We	(the entity) give ASX the following	information.		
Inf	formation about buy-back			
1	Type of buy-back	On-market buy-back		
2	Date Appendix 3C was given to ASX		3D dated 2 October	
		2014)		
	tal of all shares/units bought ve been received, before, and	back, or in relation to	which acceptances  Previous day	
	9	back, or in relation to on, previous day	-	
	9	back, or in relation to on, previous day	-	

5

	Before previous day			Previous day		
If buy-back is an on-market buy-	Highest	price	paid:	Highest	price	paid:
back	\$0.8525			\$0.7450	prios	poid:
	Lowest	price	paid:	Lowest \$0.7150	price	paid:
	\$0.5600	price	paid.	Highest under \$0.7686	price al rule	llowed 7.33:

## How many shares/units may still be bought back?

6 If the company/trust has disclosed an intention to buy back a maximum number of shares/units – the remaining number of shares/units to be bought back

20,679,223			

## **Compliance statement**

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here:

Date: 19 December 2014

(Director/Company secretary)

Print name: SUE MORGAN

== == == == ==